KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Leases (2019 - 2026)

Pacific Biosciences Of California has reported Current Leases over the past 7 years, most recently at $448000.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 95.53% year-over-year to $448000.0; the TTM value through Dec 2025 reached $448000.0, down 95.53%, while the annual FY2025 figure was $448000.0, 95.53% down from the prior year.
  • Current Leases for Q4 2025 was $448000.0 at Pacific Biosciences Of California, down from $621000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $12.5 million in Q2 2024 and troughed at $448000.0 in Q4 2025.
  • A 5-year average of $7.1 million and a median of $8.6 million in 2022 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: skyrocketed 81.12% in 2022 and later crashed 95.53% in 2025.
  • Year by year, Current Leases stood at $7.7 million in 2021, then rose by 15.25% to $8.9 million in 2022, then grew by 7.93% to $9.6 million in 2023, then grew by 4.54% to $10.0 million in 2024, then crashed by 95.53% to $448000.0 in 2025.
  • Business Quant data shows Current Leases for PACB at $448000.0 in Q4 2025, $621000.0 in Q3 2025, and $703000.0 in Q2 2025.